Literature DB >> 9813417

First-trimester multifetal pregnancy reduction: evaluation of technical aspects and risks from 2,756 cases in the literature.

H Dechaud1, M C Picot, B Hedon, P Boulot.   

Abstract

OBJECTIVE: To evaluate the technical aspects, efficacy and safety of first-trimester multifetal pregnancy reduction in the management of multifetal pregnancies, an analysis of the international literature on first-trimester multifetal pregnancy reduction was made. MATERIALS: Thirty-three studies were selected from an international review of the literature. Total fetal loss rate, risk of fetal loss after the procedure with the different techniques and gestational age at delivery were the main parameters studied. The Kruskal-Wallis test and Mann-Whitney test were used for statistical analysis.
RESULTS: 2,756 multifetal pregnancy reductions were performed (2,145 transabdominal, 363 transcervical, and 248 transvaginal procedures). Total fetal loss rates were different: 16.7% for the transabdominal, 24.8% for the transcervical and 10.9% for the transvaginal procedure (p = 0.03). The risk of fetal loss was 12% for the transabdominal, 20% for the transcervical, and 10% for the transvaginal approach at less 24 weeks of gestation (p = 0.04). There was no difference for the gestational age at the time of the procedure, the initial and final number of embryos, and the gestational age at delivery.
CONCLUSION: Because the transvaginal approach seems to be the safer procedure, surgeons may opt for it. The transcervical approach has a high fetal loss rate and should be excluded.

Mesh:

Year:  1998        PMID: 9813417     DOI: 10.1159/000020851

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  1 in total

1.  Pregnancy outcomes of different methods for multifetal pregnancy reduction: a comparative study.

Authors:  Jung Ryeol Lee; Seung-Yup Ku; Byung Chul Jee; Chang Suk Suh; Ki Chul Kim; Seok Hyun Kim
Journal:  J Korean Med Sci       Date:  2008-02       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.